Cetera Advisors LLC Buys 10,450 Shares of TherapeuticsMD Inc (NASDAQ:TXMD)

Cetera Advisors LLC grew its stake in TherapeuticsMD Inc (NASDAQ:TXMD) by 11.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,975 shares of the company’s stock after purchasing an additional 10,450 shares during the period. Cetera Advisors LLC’s holdings in TherapeuticsMD were worth $384,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Moors & Cabot Inc. acquired a new position in TherapeuticsMD during the 2nd quarter worth $25,000. Moloney Securities Asset Management LLC bought a new stake in shares of TherapeuticsMD during the 2nd quarter valued at $27,000. Highland Private Wealth Management bought a new stake in shares of TherapeuticsMD during the 2nd quarter valued at $28,000. H D Vest Advisory Services bought a new stake in shares of TherapeuticsMD during the 2nd quarter valued at $34,000. Finally, Advisor Group Inc. raised its position in shares of TherapeuticsMD by 73.2% during the 2nd quarter. Advisor Group Inc. now owns 13,960 shares of the company’s stock valued at $36,000 after acquiring an additional 5,900 shares during the last quarter. Institutional investors own 67.53% of the company’s stock.

Shares of TherapeuticsMD stock opened at $2.63 on Tuesday. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 2.85. TherapeuticsMD Inc has a 52 week low of $1.82 and a 52 week high of $6.09. The firm has a fifty day moving average of $3.25 and a two-hundred day moving average of $3.02. The stock has a market capitalization of $745.74 million, a price-to-earnings ratio of -4.46 and a beta of 1.65.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06. TherapeuticsMD had a negative net margin of 427.70% and a negative return on equity of 430.28%. The business had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $8.05 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The firm’s quarterly revenue was up 136.6% on a year-over-year basis. As a group, research analysts forecast that TherapeuticsMD Inc will post -0.7 EPS for the current fiscal year.

In other news, insider John C.K. Iv Milligan acquired 72,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was acquired at an average price of $2.75 per share, for a total transaction of $198,000.00. Following the transaction, the insider now directly owns 1,544,419 shares in the company, valued at $4,247,152.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Group L. P. Column acquired 4,387 shares of the stock in a transaction that occurred on Wednesday, October 23rd. The stock was purchased at an average price of $12.66 per share, with a total value of $55,539.42. In the last 90 days, insiders purchased 122,387 shares of company stock valued at $380,239. 18.91% of the stock is owned by corporate insiders.

Several analysts have commented on TXMD shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of TherapeuticsMD in a research report on Tuesday, October 29th. Stifel Nicolaus dropped their target price on shares of TherapeuticsMD from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Oppenheimer set a $9.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $10.11.

TherapeuticsMD Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: How liquidity affects the bid-ask spread

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.